Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis.

about

Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis.

Item

http://www.wikidata.org/entity/Q55376762

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Predictive value of serum calp ...... nts with rheumatoid arthritis.

@en

Predictive value of serum calprotectin

@nl

type

Item

label

Predictive value of serum calp ...... nts with rheumatoid arthritis.

@en

Predictive value of serum calprotectin

@nl

prefLabel

Predictive value of serum calp ...... nts with rheumatoid arthritis.

@en

Predictive value of serum calprotectin

@nl

P1476

Predictive value of serum calp ...... nts with rheumatoid arthritis.

@en

P2093

Frank H J van den Hoogen

http://www.w3.org/2001/XMLSchema#string

Leo A B Joosten

http://www.w3.org/2001/XMLSchema#string

Lieke Tweehuysen

http://www.w3.org/2001/XMLSchema#string

Noortje van Herwaarden

http://www.w3.org/2001/XMLSchema#string

Peter L van Lent

http://www.w3.org/2001/XMLSchema#string

Rogier M Thurlings

http://www.w3.org/2001/XMLSchema#string

Thomas Vogl

http://www.w3.org/2001/XMLSchema#string

P2860

Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity

Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability

Identification of S100A9 as biomarker of responsiveness to the methotrexate/etanercept combination in rheumatoid arthritis using a proteomic approach

Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach

Calprotectin--a novel marker of obesity.

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial.

Calprotectin as a biomarker for rheumatoid arthritis: a systematic review.

MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis.

Little Evidence for Usefulness of Biomarkers for Predicting Successful Dose Reduction or Discontinuation of a Biologic Agent in Rheumatoid Arthritis: A Systematic Review.

P304

e000654

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/RMDOPEN-2018-000654

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Alfons A den Broeder

Nathan den Broeder

P577

2018-04-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29657832

http://www.w3.org/2001/XMLSchema#string

P921

TNF inhibitor

TNF

P932

5892754

http://www.w3.org/2001/XMLSchema#string